Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2020 | Management of ALL patients during COVID-19

Josep-Maria Ribera • 29 Jun 2020
EHA 2020
Acute Lymphoblastic Leukemia Leukemia

Josep-Maria Ribera, MD, PhD, Germans Trias i Pujol University Hospital, Barcelona, Spain, outlines changes in the treatment and management of acute lymphoblastic leukemia (ALL) in the face of COVID-19. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Josep-Maria Ribera

1:25
BURKIMAB14: dose reduction of chemotherapy in young adults with Burkitt lymphoma
Josep-Maria Ribera • 9 Jun 2023
0:55
PhALLCON: Phase III study of ponatinib vs imatinib in newly diagnosed Ph+ ALL
Josep-Maria Ribera • 9 Jun 2023
1:02
Incorporating immunotherapy into the first-line treatment of ALL
Josep-Maria Ribera • 9 Jun 2023
1:31
PETHEMA LAL19: continuation therapy or allogeneic transplantation according to MRD & genetics in ALL
Josep-Maria Ribera • 8 Oct 2022

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals